VN March 2021

Vetnuus | Maart 2021 6 COVID-19 has raised public awareness about the role of national medicines regulatory authorities in enabling access to safe, effective and quality-assured medicines. This includes vaccines. In South Africa, the pandemic has also exposed a number of important misperceptions, among the public and health professionals. The South African Health Products Regulatory Authority is responsible for monitoring, evaluating, investigating, inspecting and registering all health products. These include medicines for human and animal use, medical devices and diagnostic tests. The authority is an independent structure, located outside the Department of Health and the public service. Funded by a combination of user fees and fiscal allocation, with a small contribution fromdonors, it is accountable to theMinister of Health. Regulatory bodies vary around the world, but the structure of the South African authority is now closer to those of other major regulators. The decision-making power is vested in the chief executive officer (CEO). The CEO can appoint a range of technical advisory committees to make recommendations to inform regulatory decisions. Members of the advisory committees are drawn from academia and private practice. Examples of regulatory decisions include: • Registration of a medicine or vaccine. Registration is required before a medicine can be marketed. • Approval to conduct a clinical trial in human volunteers of an investigational vaccine. • Approval of compassionate access to an unregistered medicine. This is done on the basis of motivation by an authorised prescriber or the Department of Health. National medicines regulatory authorities can also be proactive. For example, they can provide advice on regulatory standards. The authorities can also engage with applicants as they develop new products. For example, regulators have communicated in advance about the targets for the efficacy of COVID-9 vaccines. TheSouthAfricanauthorityhas alsocontributed toglobal regulatory efforts. And it is doing rolling reviews of two COVID-19 vaccines (Novavax; Johnson and Johnson) and is assessing a dossier for another (Pfizer). It has also approved imports of the vaccine (Oxford/ AstraZeneca) which is being manufactured in India even though it hasn’t yet been registered. It’s awaiting submission of a full dossier on the vaccine. South African authority By law, the South African Health Products Regulatory Authority is constrained to consider only three factors when it makes decisions: quality, safety and efficacy. Quality refers to the batch-to-batch reliability of the regulated product. This takes into account how it is made, packaged and distributed. Quality must be demonstrated at the time of registration. It must also be assured throughout the lifecycle of the health product. Lifecycle refers to the entire time that a product is marketed. Every medicine is associated with desired and undesirable effects. Explainer: how South Africa regulates medicines and vaccines (Source: www.theconversation.com , first published on February 10, 2021) Andy Gray, Senior Lecturer, Division of Pharmacology, University of KwaZulu-Natal Leading Article

RkJQdWJsaXNoZXIy OTc5MDU=